Table 4.
Clinicopathological characteristics of pRCC patients treated with immunotherapy.
| Variable | Entire group (n = 62) |
PTTG1 expression |
χ 2 | p-value | |
|---|---|---|---|---|---|
| Low expression (n = 19) | High expression (n = 43) | ||||
| Age at surgery (y, median ± SD) | 58.5 ± 10.4 | 59.2 ± 12.9 | |||
| BMI (kg/m2, median ± SD) | 22.5 ± 3.7 | 22.1 ± 3.1 | |||
| Tumour size (cm, median ± SD) | 6.1 ± 0.8 | 5.9 ± 1.8 | |||
| OS time (month, median ± SD) | 27.7 ± 8.3 | 50.0 ± 30.4 | |||
| PFS time (month, median ± SD) | 25.0 ± 10.0 | 41.7 ± 29.8 | |||
| Sex (n, %) | 0.904 | .342 | |||
| Male | 39, 62.9% | 12, 63.2% | 27, 62.8% | ||
| Female | 23, 37.1% | 7, 36.8% | 16, 37.2% | ||
| Laterality (n, %) | 0.163 | .687 | |||
| Left | 27, 43.5% | 9, 47.4% | 18, 41.9% | ||
| Right | 35, 56.5% | 10, 52.6% | 25, 58.1% | ||
| Tumour type | 0.011 | .916 | |||
| Type 1 pRCC | 19, 30.6% | 6, 31.6% | 13, 30.2% | ||
| Type 2 pRCC | 43, 69.4% | 13, 68.4% | 30, 69.8% | ||
| T stage at surgery (n, %) | 1.361 | .243 | |||
| T1–T2 | 33, 53.2% | 8, 42.1% | 25, 58.1% | ||
| T3–T4 | 29, 46.8% | 11, 57.9% | 18, 41.9% | ||
| N stage at surgery (n, %) | 0.001 | .978 | |||
| N0 | 39, 62.9% | 12, 63.2% | 27, 62.8% | ||
| N1 | 23, 37.1% | 7, 36.8% | 16, 37.2% | ||
| M stage at surgery (n, %) | 0.072 | .788 | |||
| M0 | 38, 61.3% | 12, 63.2% | 25, 59.5% | ||
| M1 | 24, 38.7% | 7, 36.8% | 17, 40.5% | ||
| AJCC stage at surgery (n, %) | 1.862 | .172 | |||
| I–II | 17, 27.4% | 3, 15.8% | 14, 32.6% | ||
| III–IV | 45, 72.6% | 16, 84.2% | 29, 67.4% | ||
| Furhman grade (n, %) | 1.925 | .165 | |||
| 1–2 | 3, 4.8% | 2, 10.5% | 1, 2.3% | ||
| 3–4 | 59, 95.2% | 17, 89.5% | 42, 97.7% | ||
| ICB response (n = 62) | 3.999 | .046 | |||
| PD/SD | 41, 66.1% | 16, 84.2% | 25, 58.1% | ||
| PR/CR | 21, 33.9% | 3, 15.8% | 18, 41.9% | ||
pRCC: papillary renal cell carcinoma; BMI, body mass index; AJCC: American Joint Committee on Cancer; ICB: immune checkpoint blockade. *p-value less than .05 was considered statistically significant and marked in bold.